RxDoctor Payments Data

Sarah Hill

Anatomic Pathology · Boston, MANPI 1912357138

Payments from drug & device makers

What this record shows

This record is dominated by grants: $54,000 of the $54,394 with a category attached, or 99.3%. AstraZeneca accounts for 99.3% of it on its own, with 1 other manufacturer making up the rest. Among anatomic pathology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$54,394in general payments, 2019–2025

Across 2 payments — averaging $27,197 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$54K
  • Eli Lilly$394
$1,006,776in research payments, 2019–2025

Across 8 payments — averaging $125,847 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$533K
  • Merck$380K
  • Astrazeneca UK Limited$93K

What the payments were for

  • Grants$54,00099%
  • Travel & lodging$3941%

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca1$54,000
Eli Lilly1$394

How this compares

$54,394 in reported general payments places this provider in the 95th percentile of 119 anatomic pathology providers in Massachusetts.

See all anatomic pathology providers in Massachusetts

Other anatomic pathology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →